Cipher Pharmaceuticals (CPH) Q3 2025 earnings summary

Executive summary

• Achieved strong growth in Q3 2025, with revenue up 24% year-over-year to $12.8 million, driven by U.S. Natroba sales and Canadian portfolio gains.

• Natroba sales reached $8.1 million in Q3 2025, up 4% sequentially, and contributed $22.5 million year-to-date.

• Adjusted EBITDA rose 79% to $7.3 million in Q3 2025, with net income increasing to $5.5 million from $0.3 million in Q3 2024.

• Significant debt reduction, with $17 million repaid in Q3 and $32 million year-to-date, lowering the revolving credit facility to $8 million.

• Recent acquisition of Natroba in July 2024 expanded the U.S. dermatology platform and offers market share growth opportunities.

Financial highlights

• Q3 2025 net revenue was $12.8 million, up 24% year-over-year; year-to-date revenue reached $38.2 million, up 78%.

• Canadian product portfolio revenue grew 5% in Q3 and 18% year-to-date.

• Licensing revenue declined 28% in Q3 and 44% year-to-date, mainly due to lower Absorica and Lipofen royalties.

• Adjusted EBITDA for Q3 and year-to-date was $7.3 million and $21.1 million, up 79% and 97% year-over-year.

• Gross margin was 82% in Q3 2025, up from 81% in Q3 2024.

Outlook and guidance

• Direct-to-consumer sales model for Natroba to launch in early 2026, aiming to drive further U.S. growth.

• Plans to launch Natroba in Canada, with a new drug submission to Health Canada in Q4 2025.

• Outlicensing opportunities for Natroba being explored globally, with focus on Europe and Japan.

• Actively pursuing complementary product in-licensing and acquisition opportunities aligned with U.S. operations.

• Substantial liquidity for growth, with $82 million USD growth capital available and low leverage profile.